ApoE-/-Fas-/- C57BL/6 mice: A novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia

Journal of Lipid Research

Volumn 48, Issue 4, 2007, Pages 794-805

  Feng, Xuebing ^a,c   Li, Hongyun ^a   Rumbin, Alexis A ^a   Wang, Xuping ^a   La Cava, Antonio ^a   Brechtelsbauer, Katherine ^a   Castellani, Lawrence W ^a   Witztum, Joseph L ^b   Lusis, Aldons J ^a   Tsao, Betty P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Apoptosis; Autoantibodies; Oxidized phospholipid

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN E; AUTOANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PHOSPHOLIPID;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNITY; BONE DENSITY; CONTROLLED STUDY; EXPERIMENTAL MODEL; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN BLOOD LEVEL; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NICK END LABELING; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; PRIORITY JOURNAL;

ANIMALS; APOLIPOPROTEIN B-100; ATHEROSCLEROSIS; AUTOANTIBODIES; BONE DENSITY; BONE DISEASES, METABOLIC; DISEASE MODELS, ANIMAL; FEMALE; LUPUS NEPHRITIS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATION-REDUCTION; PHOSPHOLIPIDS;

EID: 34147129553     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M600512-JLR200     Document Type: Article

References (58)

1. Bacon, P. A., R. J. Stevens, D. M. Carruthers, S. P. Young, and G. D. Kitas. 2002. Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun. Rev. 1: 338-347.
2. Borchers, A. T., C. L. Keen, Y. Shoenfeld, and M. E. Gershwin. 2004. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun. Rev. 3: 423-453.
3. Roman, M. J., B. A. Shanker, A. Davis, M. D. Lockshin, L. Sammaritano, R. Simantov, M. K. Crow, J. E. Schwartz, S. A. Paget, R. B. Devereux, and D. J. Salmon. 2003. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349: 2399-2406.
4. Asanuma, Y., A. Oeser, A. K. Shintani, E. Turner, N. Olsen, S. Fazio, M. F. Linton, P. Raggi, and C. M. Stein. 2003. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349: 2407-2415.
5. Manzi, S., E. N. Meilahn, J. E. Rairie, C. G. Conte, T. A. Medsger, Jr., L. Jansen-McWilliams, R. B. Agostino, and L. H. Kuller. 1997. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 145: 408-415.
6. Esdaile, J. M., M. Abrahamowicz, T. Grodzicky, Y. Li, C. Panaritis, B. R. du, R. Cote, S. A. Grover, P. R. Fortin, A. E. Clarke, and J. L. Senecal. 2001. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 44: 2331-2337.
7. Bultink, I. E., W. F. Lems, P. J. Kostense, B. A. Dijkmans, and A. E. Voskuyl. 2005. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum. 52: 2044-2050.
8. Redlich, K., S. Ziegler, H. P. Kiener, S. Spitzauer, P. Stohlawetz, P. Bernecker, F. Kainberger, S. Grampp, S. Kudlacek, W. Woloszczuk, J. S. Smolen, and P. Pietschmann. 2000. Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosus. Ann. Rheum. Dis. 59: 308-310.
9. Carlsten, H. 2005. Immune responses and bone loss: the estrogen connection. Immunol. Rev. 208: 194-206.
10. Lee, C., O. Almagor, D. D. Dunlop, S. Manzi, S. Spies, A. B. Chadha, and R. Ramsey-Goldman. 2006. Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids. Rheumatology (Oxford). 45: 53-60.
11. Demer, L. L. 2002. Vascular calcification and osteoporosis: inflammatory responses to oxidized lipids. Int. J. Epidemiol. 31: 737-741.
12. Frostegard, J. 2002. Autoimmunity, oxidized LDL and cardiovascular disease. Autoimmun. Rev. 1: 233-237.
13. Binder, C. J., M. K. Chang, P. X. Shaw, Y. I. Miller, K. Hartvigsen, A. Dewan, and J. L. Witztum. 2002. Innate and acquired immunity in atherogenesis. Nat. Med. 8: 1218-1226.
14. Frostegard, J. 2005. SLE, atherosclerosis and cardiovascular disease. J. Intern. Med. 257: 485-495.
15. Berliner, J. A., and A. D. Watson. 2005. A role for oxidized phospholipids in atherosclerosis. N. Engl. J. Med. 353: 9-11.
16. Navab, M., S. Y. Hama, S. T. Reddy, C. J. Ng, B. J. Van Lenten, H. Laks, and A. M. Fogelman. 2002. Oxidized lipids as mediators of coronary heart disease. Curr. Opin. Lipidol. 13: 363-372.
17. Frostegard, J., E. Svenungsson, R. H. Wu, I. Gunnarsson, I. E. Lundberg, L. Klareskog, S. Horkko, and J. L. Witztum. 2005. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum. 52: 192-200.
18. Soep, J. B., M. Mietus-Snyder, M. J. Malloy, J. L. Witztum, and E. von Scheven. 2004. Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus. Arthritis Rheum. 51: 451-457.
19. Parhami, F., A. D. Morrow, J. Balucan, N. Leitinger, A. D. Watson, Y. Tintut, J. A. Berliner, and L. L. Demer. 1997. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler. Thromb. Vasc. Biol. 17: 680-687.
20. Aprahamian, T., I. Rifkin, A. Bonegio, B. Hugel, J. M. Freyssinet, K. Sato, J. J. Castellot, and K. Walsh. 2004. Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J. Exp. Med. 199: 1121-1131.
21. Stanic, A. K., C. M. Stein, A. C. Morgan, S. Fazio, M. F. Linton, E. K. Wakeland, N. J. Olsen, and A. S. Major. 2006. Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA. 103: 7018-7023.
22. Schapira, D., A. Kabala, B. Raz, and E. Israeli. 2001. Osteoporosis in murine systemic lupus erythematosus - a laboratory model. Lupus. 10: 431-438.
23. Piedrahita, J. A., S. H. Zhang, J. R. Hagaman, P. M. Oliver, and N. Maeda. 1992. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. USA. 89: 4471-4475.
24. Croker, B. P., G. Gilkeson, and L. Morel. 2003. Genetic interactions between susceptibility loci reveal epistatic pathogenic networks in murine lupus. Genes Immun. 4: 575-585.
25. Haywood, M. E. K., N. J. Rogers, S. J. Rose, J. Boyle, A. McDermott, J. M. Rankin, V. Thiruudaian, M. R. Lewis, L. Fossati-Jimack, S. Izui, M. J. Walport, and B. J. Morley. 2004. Dissection of BXSB lupus phenotype using mice congenic for chromosome 1 demonstrates that separate intervals direct different aspects of disease. J. Immunol. 173: 4277-4285.
26. Edwards, M. H., S. Pierangeli, X. Liu, J. H. Barker, G. Anderson, and E. N. Harris. 1997. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation. 96: 4380-4384.
27. Shi, W., X. Wang, N. J. Wang, W. H. McBride, and A. J. Lusis. 2000. Effect of macrophage-derived apolipoprotein E on established atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 20: 2261-2266.
28. Binder, C. J., K. Hartvigsen, M. K. Chang, M. Miller, D. Broide, W. Palinski, L. K. Curtiss, M. Corr, and J. L. Witztum. 2004. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J. Clin. Invest. 114: 427-437.
29. Schneider, M., J. L. Witztum, S. G. Young, E. H. Ludwig, E. R. Miller, S. Tsimikas, L. K. Curtiss, S. M. Marcovina, J. M. Taylor, R. M. Lawn, T. L. Innerarity, and R. E. Pitas. 2005. High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. J. Lipid Res. 46: 769-778.
30. Zlot, C. H., L. M. Flynn, M. M. Veniant, E. Kim, M. Raabe, S. P. A. McCormick, P. Ambroziak, L. M. McEvoy, and S. G. Young. 1999. Generation of monoclonal antibodies specific for mouse apolipoprotein B-100 in apolipoprotein B-48-only mice. J. Lipid Res. 40: 76-84.
31. Muhlfeld, A. S., S. Segerer, K. Hudkins, M. D. Carling, M. Wen, A. G. Farr, J. V. Ravetch, and C. E. Alpers. 2003. Deletion of the fcgamma receptor IIb in thymic stromal lymphopoietin transgenic mice aggravates membranoproliferative glomerulonephritis. Am. J. Pathol. 163: 1127-1136.
32. Qiao, J. H., P. Z. Xie, M. C. Fishbein, J. Kreuzer, T. A. Drake, L. L. Demer, and A. J. Lusis. 1994. Pathology of atheromatous lesions in inbred and genetically-engineered mice - genetic determination of arterial calcification. Arterioscler. Thromb. 14: 1480-1497.
33. Chang, M. K., C. J. Binder, Y. I. Miller, G. Subbanagounder, J. A. Berliner, and J. L. Witztum. 2004. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J. Exp. Med. 200: 1359-1370.
34. Chang, M. K., C. Bergmark, A. Laurila, S. Horkko, K. H. Han, P. Friedman, E. A. Dennis, and J. L. Witztum. 1999. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc. Natl. Acad. Sci. USA. 96: 6353-6358.
35. Olofsson, S. O., and J. Boren. 2005. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J. Intern. Med. 258: 395-410.
36. Abedin, M., Y. Tintut, and L. L. Demer. 2004. Vascular calcification: mechanisms and clinical ramifications. Arterioscler. Thromb. Vasc. Biol. 24: 1161-1170.
37. Schilling, A. F., T. Schinke, C. Munch, M. Gebauer, A. Niemeier, M. Priemel, T. Streichert, J. M. Rueger, and M. Amling. 2005. Increased bone formation in mice lacking apolipoprotein E. J. Bone Miner. Res. 20: 274-282.
38. Parhami, F., Y. Tintut, W. G. Beamer, N. Gharavi, W. Goodman, and L. L. Demer. 2001. Atherogenic high-fat diet reduces bone mineralization in mice. J. Bone Miner. Res. 16: 182-188.
39. Houston, A., and J. O'Connell. 2004. The Fas signalling pathway and its role in the pathogenesis of cancer. Curr. Opin. Pharmacol. 4: 321-326.
40. Grainger, D. J., J. Reckless, and E. McKilligin. 2004. Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice. J. Immunol. 173: 6366-6375.
41. Herrmann, M., R. E. Voll, O. M. Zoller, M. Hagenhofer, B. B. Ponner, and J. R. Kalden. 1998. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum. 41: 1241-1250.
42. Perniok, A., F. Wedekind, M. Herrmann, C. Specker, and M. Schneider. 1998. High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus. 7: 113-118.
43. Ren, Y., J. Tang, M. Y. Mok, A. W. Chan, A. Wu, and C. S. Lau. 2003. Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum. 48: 2888-2897.
44. Emlen, W., J. Niebur, and R. Kadera. 1994. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J. Immunol. 152: 3685-3692.
45. Huber, J., A. Vales, G. Mitulovic, M. Blumer, R. Schmid, J. L. Witztum, B. R. Binder, and N. Leitinger. 2002. Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions. Arterioscler. Thromb. Vasc. Biol. 22: 101-107.
46. Lopez, L. R., D. F. Simpson, B. L. Hurley, and E. Matsuura. 2005. OxLDL/{beta}2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement. Ann. N. Y. Acad. Sci. 1051: 313-322.
47. Matsuura, E., K. Kobayashi, K. Inoue, L. R. Lopez, and Y. Shoenfeld. 2005. Oxidized LDL/beta2-glycoprotein I complexes: new aspects in atherosclerosis. Lupus. 14: 736-741.
48. Pratico, D., R. K. Tangirala, S. Horkko, J. L. Witztum, W. Palinski, and G. A. FitzGerald. 2001. Circulating autoantibodies to oxidized cardiolipin correlate with isoprostane F-2 alpha-VI levels and the extent of atherosclerosis in apoE-deficient mice: modulation by vitamin E. Blood. 97: 459-464.
49. Cyrus, T., D. Pratico, L. Zhao, J. L. Witztum, D. J. Rader, J. Rokach, G. A. FitzGerald, and C. D. Funk. 2001. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein E-deficient mice. Circulation. 103: 2277-2282.
50. Su, J., A. Georgiades, R. Wu, T. Thulin, U. de Faire, and J. Frostegard. 2006. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis. 188: 160-166.
51. Hulthe, J. 2004. Antibodies to oxidized LDL in atherosclerosis development - clinical and animal studies. Clin. Chim. Acta. 348: 1-8.
52. Svenungsson, E., K. Jensen-Urstad, M. Heimburger, A. Silveira, A. Hamsten, U. De Faire, J. L. Witztum, and J. Frostegard. 2001. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation. 104: 1887-1893.
53. Horkko, S., T. Olee, L. Mo, D. W. Branch, V. L. Woods, Jr., W. Palinski, P. P. Chen, and J. L. Witztum. 2001. Anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome recognize epitopes in both beta(2)-glycoprotein 1 and oxidized low-density lipoprotein. Circulation. 103: 941-946.
54. Hahn, B. H. 1998. Antibodies to DNA. N. Engl. J. Med. 338: 1359-1368.
55. Ohnishi, K., F. M. Ebling, B. Mitchell, R. R. Singh, B. H. Hahn, and B. P. Tsao. 1994. Comparison of pathogenic and nonpathogenic murine antibodies to DNA - antigen-binding and structural characteristics. Int. Immunol. 6: 817-830.
56. Chowdhry, I. A., C. Kowal, J. Hardin, Z. Zhou, and B. Diamond. 2005. Autoantibodies that bind glomeruli: cross-reactivity with bacterial antigen. Arthritis Rheum. 52: 2403-2410.
57. Neale, T. J., P. P. Ojha, M. Exner, H. Poczewski, B. Ruger, J. L. Witztum, P. Davis, and D. Kerjaschki. 1994. Proteinuria in passive Heymann nephritis is associated with lipid-peroxidation and formation of adducts on type-IV collagen. J. Clin. Invest. 94: 1577-1584.
58. Aprahamian, T., R. Bonegio, J. Rizzo, H. Perlman, D. J. Lefer, I. R. Rifkin, and K. Walsh. 2006. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J. Immunol. 177: 3028-3034.